app.dealroom.coAUG 212 min read$DXCM

DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake

DexCom reported Q2 2026 revenue of $1.31B, up 13.1% YoY, and EPS of $0.70, beating estimates. Silvant Capital bought a $5.4M stake, while insiders sold shares. Analysts maintain 'buy' ratings with targets up to $93. The stock trades near its 12-month high.

Original reporting

app.dealroom.co

Published Aug 21, 2026, 11:33 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 22, 2026, 1:33 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake — source image — Source · app.dealroom.co

Decision brief

The 30-second read

$DXCMBullishHigh

Why it matters

Earnings beat and fresh stakes could push the stock higher in the short term.

Market read

Strong earnings and institutional buying make DXCM a near‑term buying candidate.

What to watch

Potential competitive pressure from emerging CGM rivals and reimbursement policy changes.

Relevance 9/10Novelty 9/10Timing: post‑earnings release today

Background

DexCom's Q2 earnings beat expectations and attracted new institutional capital.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$DXCMBullishHigh confidence

Context

DexCom reported Q2 2026 revenue of $1.31B and EPS $0.70, beating consensus and driving institutional buying.

Expected impact

Potential short‑term rally toward $95‑$100 range.

Evidence & confidence

Strong top‑line growth, margin expansion, and fresh institutional stake indicate bullish momentum.

Market effects

Sector

Positive signal for diabetes‑tech and continuous glucose monitoring sector.

Regional

U.S. healthcare stocks may see modest lift.

Global

Limited to investors tracking med‑tech earnings.

Counterpoint

What could challenge this read

Insider sales and high valuation may temper upside.

Key entities

Company
DexCom, Inc.
Medical device maker of continuous glucose monitors.
Investor
Silvant Capital Management LLC
New stakeholder purchasing $5.4M of DXCM shares.

Read at source ← All news

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 27

$ABTMedAI 8/10

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott Laboratories (NYSE: ABT) received FDA De Novo authorization for Libre Duo, a wearable that monitors glucose and detects rising ketone levels. The company plans a U.S. launch in 2026. Abbott's stock is down 11.29% over the past year but up 9.2% over the past month. The FDA approval is a regulatory milestone but may not immediately impact revenue.

247wallst.com4 min

AUG 21

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

investing.com2 min

AUG 14

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.

barchart.com4 min

AUG 12

$DXCMMedAI 8/10

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom (DXCM) raised its 2026 outlook after a stronger Q2. Q2 revenue was $1.31B (+13.1% YoY) with adjusted EPS of $0.70 and adjusted operating margin of 25.1%. For 2026, management now expects revenue of $5.18-$5.25B, adjusted gross margin ~64%, operating margin 23.5%-24%, and EBITDA margin 31.5%-32%, citing G7 15-day rollout. FX and transition costs remain risks.

tradingview.com5 min